Log in

Relevant bibliographies by topics / Gcb-Dlbcl / Journal articles

To see the other types of publications on this topic, follow the link: Gcb-Dlbcl.

Journal articles on the topic 'Gcb-Dlbcl'

Author: Grafiati

Published: 7 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Gcb-Dlbcl.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pukiat, Sulada, Nuttapong Ngamphaiboon, Pooja Advani, et al. "BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy." Blood 116, no. 21 (2010): 3130. http://dx.doi.org/10.1182/blood.v116.21.3130.3130.

Full text

Abstract:

Abstract Abstract 3130 DLBCL has been recognized as a heterogeneous disease varying in molecular biology and clinical outcome. The use of genetic expression profiling has led to the sub-classification of DLBCL into germinal center B-cell like (GCB) and non-germinal center B cell like (non-GCB) based on the cell of origin of the neoplastic B-cell. Immunohistochemistry (IHC) algorithms had been developed and validated to identify GCB or non-GCB DLBCL. Deregulation of Bcl-2 family member of proteins plays an important role in the development, progression, and prognosis of various subtypes of B-ce

APA, Harvard, Vancouver, ISO, and other styles

2

Tarius, Jenifer Marsela, Hermawan Istiadi, Ika Pawitra Miranti, and Intan Rahmania Eka Dini. "THE CORRELATION BETWEEN CELL OF ORIGIN SUBTYPE WITH OVERALL SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN KARIADI GENERAL HOSPITAL SEMARANG." DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) 9, no. 3 (2020): 252–58. http://dx.doi.org/10.14710/dmj.v9i3.27504.

Full text

Abstract:

Background: DLBCL is the most common type of NHL in the world. DLBCL based on cell of origin is divided into GCB and non-GCB. The diagnosis of DLBCL has not been routinely done to its cell of origin, and there have not been many studies that discuss the DLBCL subtype and the overall survival of the patients, especially in Kariadi General Hospital. This study aims to determine the correlation of DLBCL cell of origin with the 2-year overall survival of DLBCL patients in Kariadi General Hospital. Methods: This is an observational analytic study of 40 DLBCL patients in Kariadi General Hospital fro

APA, Harvard, Vancouver, ISO, and other styles

3

Gandhi, Shipra, Vishala T. Neppalli, George Deeb, Myron S. Czuczman, and Francisco J. Hernandez-Ilizaliturri. "Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 122, no. 21 (2013): 5064. http://dx.doi.org/10.1182/blood.v122.21.5064.5064.

Full text

Abstract:

Abstract Background DLBCL is the most common type of non-Hodgkin lymphoma, which demonstrates morphologic, immunophenotypic, molecular, and clinical heterogeneity. Gene expression profiling studies define two molecular subtypes of DLBCL, namely germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL. Hans' algorithm was developed to provide an immunohistochemical correlation to the molecular subtypes of DLBCL. In the pre and post-rituximab era, ABC subtype of DLBCL is known to demonstrate poor overall survival when compared to GCB subtype. In addition, relapsed or primary refra

APA, Harvard, Vancouver, ISO, and other styles

4

Hayama, Miyuki, Masataka Okamoto, Yuki Hagiwara, et al. "Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era." Blood 116, no. 21 (2010): 1800. http://dx.doi.org/10.1182/blood.v116.21.1800.1800.

Full text

Abstract:

Abstract Abstract 1800 Rituximab combination chemotherapy has significantly improved the treatment outcome of diffuse large B-cell lymphoma (DLBCL). Therefore, the prognostic factors of DLBCL in the rituximab era are different from previously reported prognostic factors. Biological prognostic markers have been analyzed to help understand the biologic basis of treatment outcome. Hans, et al. reported that patients with non-germinal center B-cell like (GCB)-type DLBCL had a significantly poorer prognosis than those with GCB-type DLBCL in the pre-rituximab era. In patients who received rituximab

APA, Harvard, Vancouver, ISO, and other styles

5

Kharchenko, Yevgeniya, Tatyana Semiglazova, Anna Artemeva, et al. "PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA." Problems in oncology 66, no. 1 (2020): 79–89. http://dx.doi.org/10.37469/0507-3758-2020-66-1-79-89.

Full text

Abstract:

Aim: To identify incidence and prognostic impact of different IHC and molecular genetic markers in Diffuse Large B-cell lymphoma. Methods: We analyzed 215 patients with DLBCL who received treatment from 2008 to 2016. We assess expression of different IHC markers, defined DLBCL to GCB and non-GCB subtypes by Hans-algorithm and performed FISH to evaluate MyC, BcL2 and BCL6 translocations. Results: Median follow-up was 29 months. Non-GCB DLBCL were identified in 44 pts (62,9%), GCB-subtype in 26 pts (37,1%). Median PFS in non-GCB DlBCL was 46,0 months, in GCB DLBCL median PFS and 75% quartile was

APA, Harvard, Vancouver, ISO, and other styles

6

Adhi Pangarsa, Eko, Desta Nur Ewika Ardini, Daniel Rizky та ін. "The association of Hypoxia-Inducible Factor-2α (HIF-2α) overexpression score with Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (Non-GCB) subtypes of Diffuse Large B-cell Lymphoma (DLBCL)". Bali Medical Journal 12, № 3 (2023): 2456–62. http://dx.doi.org/10.15562/bmj.v12i3.4521.

Full text

Abstract:

Link of Video Abstract: https://www.youtube.com/watch?v=KF58IGGdWmc Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. It is classified into homogeneous subtypes, namely Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (GCB), with the latter associated with worse survival outcomes. Increased expression of Hypoxia-Inducible Factor-2α (HIF-2α) is often observed in DLBCL and has been correlated with enhanced angiogenesis, suggesting its potential as a prognostic factor in managing DLBCL. The study evaluates the association bet

APA, Harvard, Vancouver, ISO, and other styles

7

Mishima, Yuko, Masahiro Yokoyama, Noriko Nishimura, et al. "R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL." Blood 126, no. 23 (2015): 1507. http://dx.doi.org/10.1182/blood.v126.23.1507.1507.

Full text

Abstract:

Abstract Introduction: There are various poor prognosis factors in diffuse large B cell lymphoma (DLBCL). CD5 positive (CD5+) is estimated as one of the poor prognosis markers in DLBCL. CD5+ DLBCL is completely distinguished from CLL or Mantle cell lymphoma, and de Novo CD5+ DLBCL is related to a high incidence of cytogenetic abnormalities of 8p21 and 11q13. In many cases, CD5+ DLBCL is associated with an aggressive clinical status and advanced stages. Several chromosomal studies have demonstrated the gene expression was similar to non-GCB type of DLBCL. In the clinical phase, it is easy to ex

APA, Harvard, Vancouver, ISO, and other styles

8

Chavez, Julio, Mark Walsh, Francisco J. Hernandez-Ilizaliturri, Anjana Elefante, and Myron S. Czuczman. "Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy." Blood 114, no. 22 (2009): 623. http://dx.doi.org/10.1182/blood.v114.22.623.623.

Full text

Abstract:

Abstract Abstract 623 Gene expression profiling has successfully distinguished three subtypes of DLBCL with different biology and response to treatment: 1) germinal center B-cell (GCB); and 2) non-germinal center lymphomas, that include: activated B-cell-like (ABC) and Type 3 subtypes. Currently, immunohistochemical (IHC) analysis of lymphoma biopsy specimens appear to be a more widely applicable methodology (i.e. compared to gene microarray analysis) to use in order to differentiate between subtypes of DLBCL. While the clinical benefit of adding rituximab to CHOP or CHOP-like chemotherapy as

APA, Harvard, Vancouver, ISO, and other styles

9

Van Meerten, Tom, Renee Bouwstra, Yuan He, et al. "CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 132, Supplement 1 (2018): 2852. http://dx.doi.org/10.1182/blood-2018-99-114561.

Full text

Abstract:

Abstract CD47 is an immune-checkpoint protein that binds SIRPa on immune cells to deliver an inhibitory "don't eat me" signal. CD47 is a prominent new target in B-cell malignancies, in which CD47 antibody in combination with the CD20 antibody rituximab (R) is explored in clinical trials. Addition of R to CHOP chemotherapy significantly improves survival of patients with DLBCL, but how CD47 expression contributes to this positive impact of R on patient outcome is currently unclear. Especially in the context of the different cell-of-origin DLBCL subtypes (Germinal Center B-cell (GCB) vs non-GCB

APA, Harvard, Vancouver, ISO, and other styles

10

Niitsu, Nozomi, Naoki Takahashi, Tadashi Yoshino, Masataka Okamoto, and Shigeo Nakamura. "Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era." Blood 126, no. 23 (2015): 3911. http://dx.doi.org/10.1182/blood.v126.23.3911.3911.

Full text

Abstract:

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of diseases in terms of morphology, immunohistochemistry and molecular features. The prognostic factors of DLBCL in the rituximab era are different from previously reported prognostic factors. Hans, et al. reported that patients with non-germinal center B-cell like (GCB)-type DLBCL had a significantly poorer prognosis than those with GCB-type DLBCL in the pre-rituximab era. In patients who received rituximab combination chemotherapy, there is a report that did not find a difference in survival ratio between t

APA, Harvard, Vancouver, ISO, and other styles

11

Alam, SM Mahbubul, and Ahmed Khaled. "Immunophenotypic characteristics of Diffuse Large Bcell Lymphoma." Bioresearch Communications 8, no. 1 (2021): 1049–52. http://dx.doi.org/10.3329/brc.v8i1.57043.

Full text

Abstract:

Introduction: Immunohistochemistry (IHC) is essential in the diagnostic workup of Diffuse Large B cell lymphoma (DLBCL). Determination of biological heterogenicity of Diffuse Large B-cell Lymphoma (DLBCL) is critical to institute precise treatment and predict prognosis. IHC confirms B cell phenotypes, reflects molecular subtype based on cell of origin and determines other immunophenotypic characteristics. Methods and Material: All cases of DLBCL diagnosed in 2020 (Jan-Dec) in histopathology department of Evercare Hospital Dhaka were included in this study. Histopathological sections were stain

APA, Harvard, Vancouver, ISO, and other styles

12

Slimani, Yasmine, Fouzia Hali, and Fatima-Zohra El Fatoiki. "Triple-negative diffuse large B-cell lymphoma: A distinct entity." Our Dermatology Online 12, no. 4 (2021): 427–29. http://dx.doi.org/10.7241/ourd.20214.17.

Full text

Abstract:

The Hans algorithm categorizes the diffuse large B-cell lymphoma (DLBCL) into two major subtypes: the germinal center B-cell-like (GCB) DLBCL and the non-GCB DLBCL. This classification is based on three immunohistochemical markers: CD10, BCL6, and MUM1. The non-GCB subtype is associated with lower overall survival (OS) and progression-free survival (PFS) rates compared to the GCB. DLBCL without positive staining for these three markers (CD10–, BCL6–, MUM1–), also called a triple negative or TN, are classified as the non-GCB subtype. However, they show different clinical characteristics and bet

APA, Harvard, Vancouver, ISO, and other styles

13

Nooruddin, Zohra, Zenggang Pan, Lilyana Gross, et al. "Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes." Blood 128, no. 22 (2016): 3054. http://dx.doi.org/10.1182/blood.v128.22.3054.3054.

Full text

Abstract:

Abstract Background : Post Transplant Lymphoproliferative disorder (PTLD) represents a distinct and rare complication following solid organ transplantation (SOT). Insight into the biology of this disorder is limited to retrospective reviews and case series. In one of the first reports for post-transplant Diffuse Large B cell Lymphoma (PT-DLBCL) cases, we demonstrated a higher incidence and improved outcomes in PT-DLBCL non-germinal center B-cell (non-GCB) subtype compared to PT-DLBCL germinal center B-cell (GCB) Subtype. Published data suggests immunocompetent DLBCL non-GCB subtypes are less c

APA, Harvard, Vancouver, ISO, and other styles

14

Costa, Luciano J., Andrew L. Feldman, Ivana N. Micallef, et al. "Germinal Center B Cell and Non-Germinal Center B Cell-Like DLBCL Have Similar Clinical Features at the Time of Progression and Comparable Outcome Following Autologous HSC Transplantation." Blood 110, no. 11 (2007): 1901. http://dx.doi.org/10.1182/blood.v110.11.1901.1901.

Full text

Abstract:

Abstract Background: Germinal center B cell-like (GCB) DLBCL, as determined by gene expression profiling or immunohistochemistry, is more likely to be cured by initial conventional chemoimmunotherapy than non-germinal center B cell-like (non-GCB) DLBCL. For patients with relapsed or refractory chemosensitive DLBCL, high-dose chemotherapy and autologous hematopoietic stem cell (HSC) transplant is considered standard-of-care treatment, but it is unknown whether the outcome of these patients is similarly influenced by the subtype of DLBCL. We therefore explored the differences between patients wi

APA, Harvard, Vancouver, ISO, and other styles

15

Lossos, Izidore S., XiaoQing Lu, Feiying Ding, Manuel Rosado, Ash A. Alizadeh, and Hovav Nechushtan. "Distinct IL-4 Intracellular Signaling in Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B-Cell Lymphoma: Novel Opportunities for Therapeutic Interventions." Blood 104, no. 11 (2004): 244. http://dx.doi.org/10.1182/blood.v104.11.244.244.

Full text

Abstract:

Abstract Gene expression profiling studies sub-classified diffuse large B-cell lymphomas (DLBCL) into two clinically distinct types: germinal center B cell (GCB)-like and activated B-cell (ABC)-like tumors, characterized by long and short survival, respectively. At least two markers of the GCB-phenotype - BCL6 and HGAL - are IL-4 target genes whose high expression independently predicts better overall survival. Gene expression analysis of DLBCL also demonstrated higher levels of mRNA expression of components of the IL-4 signaling pathway (IL-4Rα, IRS, p110 subunit of PI-3 kinase, and PKC delta

APA, Harvard, Vancouver, ISO, and other styles

16

Rani, E. R. Jyothi, Jasmin Scaria, and P. P. Sathi. "Analysis of Diffuse Large B Cell Lymphoma using Immunohistochemistry to Identify Double Expressor Diffuse Large B Cell Lymphoma among Germinal Centre and Non Germinal Centre B Cell Subtypes." Medical Journal of Dr. D.Y. Patil Vidyapeeth 17, no. 4 (2024): 707–12. http://dx.doi.org/10.4103/mjdrdypu.mjdrdypu_100_23.

Full text

Abstract:

ABSTRACT Background: Diffuse large B cell lymphoma (DLBCL) within non-Hodgkin lymphoma has several morphologic and clinicopathologic variants. DLBCL has two prognostically important subtypes, germinal center B cell (GCB) and nongerminal center (Non-GCB) with the non-GCB having an inferior outcome. Immunohistochemical co-expression of cellular myelocytomatosis (CMYC) and BCL2 in DLBCL has poor prognosis and is considered as double-expressor lymphoma (DEL). Aims and Objectives: This study was done to identify DEL using immunohistochemistry among GCB and non-GCB DLBCL and to assess their treatmen

APA, Harvard, Vancouver, ISO, and other styles

17

Ananthamurthy, Anuradha, and Megha Murali. "An immunohistochemical study of diffuse large B-cell lymphoma with molecular subtyping based on Hans algorithm." Indian Journal of Pathology and Microbiology 67, no. 3 (2023): 564–68. http://dx.doi.org/10.4103/ijpm.ijpm_683_22.

Full text

Abstract:

ABSTRACT Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma accounting for about 40% of all lymphomas. The international prognostic index (IPI), which relies on clinical and laboratory parameters, is used as a prognostic tool in DLBCL. In this study, we have included cases of DLBCL not otherwise specified (NOS) type to test the usefulness of the biological subclassification of DLBCL by immunohistochemistry (IHC) using the Hans algorithm into the germinal center B-like (GCB) type and nongerminal center (non-GCB) type. We correlated the subtypes with t

APA, Harvard, Vancouver, ISO, and other styles

18

Julianty, Patricia Fransisca, Maria Francisca Ham, Kusmardi Kusmardi, and Agnes Stephanie Harahap. "CD30 Expression in Germinal Center B-cell-like and non-Germinal Center B-cell-like Subtypes of Diffuse Large B-cell Lymphoma." Open Access Macedonian Journal of Medical Sciences 8, B (2020): 375–80. http://dx.doi.org/10.3889/oamjms.2020.4645.

Full text

Abstract:

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common and most heterogeneous type of non-Hodgkin lymphoma. With current therapeutic modalities, 30%–40% of DLBCL cases still experience recurrence. The discovery of CD30 expression in DLBCL in several studies has opened up alternative opportunities for new target therapies. AIM: This cross-sectional study aimed to determine CD30 expression in DLBCL and its difference in expression in germinal center B-cell such as (GCB) and non-GCB subtypes. METHODS: The sample consisted of 25 GCB and 25 non-GCB cases based on immunohis

APA, Harvard, Vancouver, ISO, and other styles

19

Lenz, Georg, George Wright, Sandeep Dave, et al. "Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy." Blood 110, no. 11 (2007): 348. http://dx.doi.org/10.1182/blood.v110.11.348.348.

Full text

Abstract:

Abstract Gene expression profiling has been used to distinguish two major subtypes of diffuse large B cell lymphoma (DLBCL), termed germinal center B cell-like (GCB) DLBCL and activated B cell-like (ABC) DLBCL. Following CHOP-like chemotherapy, GCB and ABC DLBCLs had distinct 5-year survival rates of ∼60% and ∼30%, respectively. Prognostic gene expression signatures in CHOP-treated DLBCL include the lymph node signature, which reflects a non-malignant host response, the MHC class II signature, both favorable when expressed and the proliferation signature which is adverse when expressed. The ad

APA, Harvard, Vancouver, ISO, and other styles

20

Nechushtan, Hovav, Joseph D. Rosenblatt, and Izidore S. Lossos. "IL-4 Affects Proliferation, Chemosensitivity-and Rituximab Sensitivity of Germinal Center B-Cell like (GCB) and Activated B-Cell like (ABC) Diffuse Large B-Cell Lymphoma Differently." Blood 104, no. 11 (2004): 242. http://dx.doi.org/10.1182/blood.v104.11.242.242.

Full text

Abstract:

Abstract Diffuse Large B-cell Lymphoma (DLBCL) represent a diverse group of lymphoid neoplasms with heterogeneous clinical, histological, immunophenotypic, cytogenetic and molecular genetic features. Approximately 50% of DLBCL patients are not cured by the standard combination chemotherapy regimens. DLBCL can be subclassified into GCB-like DLBCL which are characterized by expression of genes normally expressed in germinal center B cells, and having a significantly better overall survival (OS) than the ABC-like DLBCL, which are characterized by expression of genes induced during in vitro activa

APA, Harvard, Vancouver, ISO, and other styles

21

Shabir, Muhammad Hamad, Hafeez Ud Din, Rafia Mahmood, and Umair Aslam Shehzad. "Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population." Applied Immunohistochemistry & Molecular Morphology 33, no. 1 (2024): 10–14. https://doi.org/10.1097/pai.0000000000001239.

Full text

Abstract:

MYD88 L265P mutation is a gain-of-function driver mutation. It is observed in a significant proportion of Waldenstrom macroglobulinemia and activated B-cell subtype of diffuse large B-cell lymphoma (DLBCL; non-germinal center subtype). The incidence of this mutation in the subtypes of DLBCL has not yet been documented in the Pakistani population. This study aimed to ascertain the frequency and association of MYD88 L265P mutation within 2 subtypes of DLBCL, germinal center B-cell-like (GCB) and non-GCB B-cell lymphoma (non-GCB), in the local population. This cross-sectional study was conducted

APA, Harvard, Vancouver, ISO, and other styles

22

Locatelli, Silvia L., Roberto Papait, Giuseppa Careddu, et al. "Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 124, no. 21 (2014): 2253. http://dx.doi.org/10.1182/blood.v124.21.2253.2253.

Full text

Abstract:

Abstract INTRODUCTION: Lenalidomide monotherapy exerts clinical activity in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) with better response rate and progression-free survival being recorded in activated B-cell-like (ABC) rather than germinal center B-cell-like (GCB)-DLBCL. Reasons for such a difference are likely due to different expression of key molecules involved in mediating activity of Lenalidomide, such as Interferon regulatory factor 4(IRF4) and cereblon (CRBN). Evidences supporting the key role of DNA methylation and histone modifications in regulating genome stability a

APA, Harvard, Vancouver, ISO, and other styles

23

Kleinstern, Geffen, Dennis P. Robinson, Lisa M. Rimsza, et al. "Abstract 741: Evaluation of etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin." Cancer Research 82, no. 12_Supplement (2022): 741. http://dx.doi.org/10.1158/1538-7445.am2022-741.

Full text

Abstract:

Abstract Background: DLBCL is the most common non-Hodgkin lymphoma subtype in western countries and is clinically heterogeneous. Gene expression profiling has identified two major biologically distinctive DLBCL subtypes defined by their cell-of-origin (COO): germinal center B-cell (GCB) - characterized by BCL2 rearrangement and C-REL amplification, and activated B-cell (ABC) - characterized by constitutive activation of the NF-kB pathway. We evaluated putative DLBCL risk factors for etiologic heterogeneity as defined by COO. Methods: We used a clinic-based study of newly diagnosed NHL cases an

APA, Harvard, Vancouver, ISO, and other styles

24

Fu, Kai, Dennis D. Weisenburger, William W. L. Choi, et al. "Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma." Journal of Clinical Oncology 26, no. 28 (2008): 4587–94. http://dx.doi.org/10.1200/jco.2007.15.9277.

Full text

Abstract:

Purpose Diffuse large B-cell lymphoma (DLBCL) includes at least two prognostically important subtypes (ie, germinal center B-cell–like [GCB] and activated B-cell–like [ABC] DLBCL), which initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining. However, with the addition of rituximab to standard chemotherapy, the prognostic significance of this subclassification of DLBCL is unclear. Patients and Methods We studied 243 patient cases of de novo DLBCL, which included 131 patient cases treated with rituximab plus standard chemotherapy (rituximab g

APA, Harvard, Vancouver, ISO, and other styles

25

Cao, Yabing, Ying Huang, Sheng Ye, and Tongyu Lin. "Prognostic impact of immunohistochemically defined germinal center B-cell and nongerminal center B-cell subtypes of diffuse large B-cell lymphoma in rituximab era." Journal of Clinical Oncology 30, no. 15_suppl (2012): e18517-e18517. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18517.

Full text

Abstract:

e18517 Background: Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. Methods: We studied 204 patients with de novo DLBCL (107 treated with CHOP; 97 treated with R-CHOP); patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10 and MUM1 protein expression. The relationships between clinical characteristics, survival data and immunophenotype were studied. Results: The median follow-up was 51months for CHOP group and 56 months for R-CHOP group. The 5-y

APA, Harvard, Vancouver, ISO, and other styles

26

Huang, Ying, Sheng Ye, Yabing Cao, et al. "Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients." Scientific World Journal 2012 (2012): 1–7. http://dx.doi.org/10.1100/2012/897178.

Full text

Abstract:

Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), r

APA, Harvard, Vancouver, ISO, and other styles

27

Dunleavy, Kieron, Stefania Pittaluga, Myron S. Czuczman, et al. "Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma." Blood 113, no. 24 (2009): 6069–76. http://dx.doi.org/10.1182/blood-2009-01-199679.

Full text

Abstract:

Abstract Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed distinct molecular subtypes that include germinal center B cell–like (GCB) and activated B cell–like (ABC) DLBCL. ABC DLBCL has a worse survival after upfront chemotherapy and is characterized by constitutive activation of the antiapoptotic nuclear factor–kappa B (NF-κB) pathway, which can inhibit chemotherapy. We hypothesized that inhibition of NF-κB might sensitize ABC but not GCB DLBCL to chemotherapy and improve outcome. As the proteasome inhibitor bortezomib can inhibit NF-κB through blocking IκBα deg

APA, Harvard, Vancouver, ISO, and other styles

28

Wenzl, Kerstin, Bryce Manso, Yan W. Asmann, et al. "Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma." Blood 128, no. 22 (2016): 2935. http://dx.doi.org/10.1182/blood.v128.22.2935.2935.

Full text

Abstract:

Abstract Gene expression profiling has shown that diffuse large B-cell lymphoma (DLBCL) clusters into three major subtypes based on similarity in expression patterns to their cell of origin (COO): germinal center B-cell-like (GCB-DLBCL), activated B-cell-like DLBCL (ABC-DBLCL) and primary mediastinal B-cell lymphoma (PMBCL). These subtypes of DLBCLs are associated with distinctly different overall survival rates after standard immunochemotherapy. However, clinical and prognostic heterogeneity remains within COO subsets and strategies are needed to further stratify patients to identify and targ

APA, Harvard, Vancouver, ISO, and other styles

29

De Paepe, Pascale, Ruth Achten, Gregor Verhoef, et al. "Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas." Journal of Clinical Oncology 23, no. 28 (2005): 7060–68. http://dx.doi.org/10.1200/jco.2005.15.503.

Full text

Abstract:

Purpose The reliability of immunohistochemistry for subdividing diffuse large B-cell lymphomas (DLBCL) into germinal center B-cell-like (GCB) and non-GCB prognostic subgroups is debated. In this study we evaluated the prognostic significance of such subgrouping on a series of 153 DLBCL patients. Furthermore, we investigated whether both subgroups could comprise clinicopathologic entities recognized by their morphology and characterized by a distinct phenotype, specific genetic abnormalities, and clinical characteristics. Patients and Methods All samples from patients were reviewed and morpholo

APA, Harvard, Vancouver, ISO, and other styles

30

Xu-Monette, Zijun Y., Ling Li, John C. Byrd, et al. "Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma." Blood 128, no. 26 (2016): 3083–100. http://dx.doi.org/10.1182/blood-2016-05-715094.

Full text

Abstract:

Key Points CD37 positivity predicts significantly better survival for DLBCL, and is superior to other prognostic factors in GCB-DLBCL. CD37 loss is an important risk factor for R-CHOP resistance in both GCB- and ABC-DLBCL.

APA, Harvard, Vancouver, ISO, and other styles

31

Dekker, Joseph D., Daechan Park, Arthur L. Shaffer, et al. "Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1." Proceedings of the National Academy of Sciences 113, no. 5 (2016): E577—E586. http://dx.doi.org/10.1073/pnas.1524677113.

Full text

Abstract:

High expression of the forkhead box P1 (FOXP1) transcription factor distinguishes the aggressive activated B cell (ABC) diffuse large B-cell lymphoma (DLBCL) subtype from the better prognosis germinal center B-cell (GCB)-DLBCL subtype and is highly correlated with poor outcomes. A genetic or functional role for FOXP1 in lymphomagenesis, however, remains unknown. Here, we report that sustained FOXP1 expression is vital for ABC-DLBCL cell-line survival. Genome-wide analyses revealed direct and indirect FOXP1 transcriptional enforcement of ABC-DLBCL hallmarks, including the classical NF-κB and MY

APA, Harvard, Vancouver, ISO, and other styles

32

Waller, Rosalie Griffin, Dennis P. Robinson, Anne J. Novak, et al. "Abstract 1181: Etiologic heterogeneity of genetic risk for DLBCL cell-of origin molecular subtypes." Cancer Research 83, no. 7_Supplement (2023): 1181. http://dx.doi.org/10.1158/1538-7445.am2023-1181.

Full text

Abstract:

Abstract Diffuse large B-cell lymphoma (DLBCL) is clinically and biologically heterogenous. Based on gene expression profiling of the tumor, DLBCL is classified into two major molecular subtypes linked to cell-of-origin (COO): germinal center (GCB) and activated B-Cell (ABC). The GCB subtype is characterized by a high prevalence of somatic mutations, particularly in apoptosis genes (e.g., BCL2) which is characteristic of follicular lymphoma (FL, another GCB lymphoma). The development of the validated NanoString gene expression test as well as immunohistochemistry markers that work in formalin-

APA, Harvard, Vancouver, ISO, and other styles

33

Kim, Yu Ri, Soo-Jeong Kim, June-Won Cheong, et al. "Upfront Autologous Stem Cell Transplantation Overcome the poor Prognosis of Non-Germinal Center Subtype of diffuse Large B-Cell Lymphoma in Patients with Advanced Stage and Elevated Serum Lactate Dehydrogenase." Blood 124, no. 21 (2014): 3998. http://dx.doi.org/10.1182/blood.v124.21.3998.3998.

Full text

Abstract:

Abstract Introduction: The role of frontline autologous hematopoietic stem cell transplantation (ASCT) high-risk diffuse large B-cell lymphoma (DLBCL) is still controversial. We investigated the role of upfront ASCT as consolidation for high-risk DLBCL treated with rituximab containing chemotherapy according to molecular classification. Methods: A total of 195 newly diagnosed DLBCL patients with advanced stage and elevated serum lactate dehydrogenase from three centers were retrospectively analyzed. All patients achieved more than partial response (PR) after completing conventional chemotherap

APA, Harvard, Vancouver, ISO, and other styles

34

Soo, Joanne, David Matthew Kurtz, Florian Scherer, et al. "Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA." Journal of Clinical Oncology 35, no. 15_suppl (2017): 7538. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7538.

Full text

Abstract:

7538 Background: Patients with diffuse large B cell lymphoma (DLBCL) exhibit significant differences in clinical outcome based on cell-of-origin (COO). Patients are categorized as having germinal-center-like (GCB) or activated-B-cell-like (ABC) disease based on RNA microarray and histopathological analyses of tumor biopsies. We recently described an accurate sequencing-based method for determination of COO in DLBCL utilizing stereotyped differences in mutations (Scherer et al., 2016). Here, we further explore the mutational patterns in patients with differing molecular subtypes of DLBCL based

APA, Harvard, Vancouver, ISO, and other styles

35

Foureau, David, Lawrence J. Druhan, Nury M. Steuerwald, et al. "Cytokine Profiling of ABC-Subtype and GCB-Subtype Diffuse Large B Cell Lymphoma: Systemic Nfkb Activation and Impact on Myeloid-Derived Suppressor Cells Distribution." Blood 126, no. 23 (2015): 2666. http://dx.doi.org/10.1182/blood.v126.23.2666.2666.

Full text

Abstract:

Abstract Background. Among patients with newly diagnosed diffuse large B cell lymphoma (DLBCL), undergoing standard immunochemotherapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), overall survival is significantly worse for those with activated B cell-like (ABC) subtype compared with germinal center B cell-like (GCB) subtype. Among the key differences between DLBCL subtypes, constitutive activation of nuclear factor kappa B (NFκB) in the ABC-subtype has been associated with a rise of circulating myeloid-derived suppressor cells (MDSC). Patients and Methods. In th

APA, Harvard, Vancouver, ISO, and other styles

36

Takizawa, Jun, Sadao Aoki, Akihito Momoi, et al. "BCL6 Rearrangement Detected by FISH Analysis Is a Poor Prognostic Factor in the “Non-Germinal Center Phenotype” of Diffuse Large B-Cell Lymphoma." Blood 108, no. 11 (2006): 4620. http://dx.doi.org/10.1182/blood.v108.11.4620.4620.

Full text

Abstract:

Abstract Background: Diffuse large B-cell lymphoma (DLBCL), which is the most common type of adult non-Hodgkin lymphoma, is considered to be heterogeneous in cytogenetics, immunophenotype and clinical feature. As the results of gene expression profiling, DLBCL can be divided into prognostically significant 3 subgroups of germinal center B-like (GCB), activated B-like and type 3. Chromosomal translocations affecting the BCL6 locus at the 3q27 locus are common in DLBCL, however, the prognostic significance of BCL6 rearrangement is still controversial. Methods: Twenty-six cases of DLBCL were exam

APA, Harvard, Vancouver, ISO, and other styles

37

Havranek, Ondrej, Jingda Xu, Stefan Koehrer, et al. "Molecular Aspects of Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma Provide Biomarkers and Targets for Specific Inhibition." Blood 128, no. 22 (2016): 779. http://dx.doi.org/10.1182/blood.v128.22.779.779.

Full text

Abstract:

Abstract Introduction. Targeting antigen-driven B-cell receptor (BCR) signaling with the BTK inhibitor ibrutinib is clinically effective against most B-cell lymphomas, including activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), but not germinal center B-cell (GCB) DLBCL. We have formally confirmed that GCB-DLBCL cell lines utilize tonic BCR signaling, by showing: 1) sensitivity (variable) to knockout (KO) of the BCR, SYK, and CD19; 2) dependence on CD79A ITAM phosphorylation; and 3) independence from BCR antigen specificity. However, uncertainty remains about molecular events in upst

APA, Harvard, Vancouver, ISO, and other styles

38

Zhao, Fengyi, Lei Zhang, Yan Qin, et al. "Characterization of Methylation Patterns in Diffuse Large B Cell Lymphoma By Genome-Wide Methylation Analysis." Blood 134, Supplement_1 (2019): 1243. http://dx.doi.org/10.1182/blood-2019-131656.

Full text

Abstract:

Background: Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide. Although the reference standard for identifying of the cell types is considered of gene expression profiling (GEP). But immunohistochemistry (IHC) is the most common method commercially available. The purpose of this study was to characterize the circulating cell-free DNA (cfDNA) methylation profile in DLBCL and to compare this profile with methylation observed in formalin fixed paraffin-embedded (FFPE) tissues. Additional efforts were made to correlate the observed methylation patterns

APA, Harvard, Vancouver, ISO, and other styles

39

Gupta, Mamta, Guangzhen Hu, Steven Offer, et al. "Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes." Blood 120, no. 21 (2012): 2655. http://dx.doi.org/10.1182/blood.v120.21.2655.2655.

Full text

Abstract:

Abstract Abstract 2655 Diffuse large B cell lymphoma (DLBCL) has been classified into two distinct molecular subtypes: germinal center B cell–like (GCB), non-germinal centre-like (non-GCB). To improve outcomes for DLBCL patients, it is necessary to identify additional novel targets within GCB and non-GCB classifications to further stratify patients for prognosis and assist in choosing therapy for the individual patient. We have recently demonstrated that STAT3 activation is frequent in the DLBCL tumors, however the exact molecular mechanism(s) of STAT3 activation in DLBCL tumors are not known.

APA, Harvard, Vancouver, ISO, and other styles

40

Alcoceba, Miguel, Elena Sebastián, Ana Balanzategui, et al. "Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma." Blood 120, no. 21 (2012): 1589. http://dx.doi.org/10.1182/blood.v120.21.1589.1589.

Full text

Abstract:

Abstract Abstract 1589 Introduction: Acquired potentially N-glycosylation sites are produced by somatic hypermutation (SHM) in the immunoglobulin (Ig) variable region. This phenomenon is produced in ∼9% of normal B-cells and seems to be related to certain B-cell lymphoproliferative disorders (B-LPDs) such as follicular lymphoma (FL, 79%), endemic Burkitt lymphoma (BL, 82%) and diffuse large B-cell lymphoma (DLBCL, 41%). These data suggest that new potential N-glycosylation sites could be related to germinal center B (GCB)-LPDs. By contrast, in other B-LPDs, such as chronic lymphocytic leukemia

APA, Harvard, Vancouver, ISO, and other styles

41

Nowakowski, Grzegorz S., Betsy LaPlant, William R. Macon, et al. "Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study." Journal of Clinical Oncology 33, no. 3 (2015): 251–57. http://dx.doi.org/10.1200/jco.2014.55.5714.

Full text

Abstract:

Purpose Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone); this new combination is known as R2CHOP. The goal of this phase II study was to evaluate the efficacy of this combination in newly diagnosed DLBCL. Patients and Methods Eligible patients were adults with newly diagnosed untreated stages II to IV CD20+ DLBCL. Patients received lenalidomide 25 mg orally per day on days 1 through 10 with standar

APA, Harvard, Vancouver, ISO, and other styles

42

Gozgit, Joseph M., Youngchul Song, Scott Wardwell, Sara Nadworny, Yaoyu Ning, and Victor M. Rivera. "Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models." Blood 126, no. 23 (2015): 4000. http://dx.doi.org/10.1182/blood.v126.23.4000.4000.

Full text

Abstract:

Abstract Introduction Diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises 2 major molecular subtypes: germinal center B-cell-like (GCB) and activated B cell-like (ABC). Although standard therapy (rituximab+ chemotherapy [R-CHOP]) is effective in most patients (pts), a significant proportion do not achieve durable remissions. Treatment of relapsed and refractory DLBCL pts with targeted therapy, such as the BTK inhibitor ibrutinib, has shown some promise; however, responses are mostly restricted to the ABC subtype. Treatment options for pts with r

APA, Harvard, Vancouver, ISO, and other styles

43

Zajdel, Michalina, Łukasz Michał Szafron, Agnieszka Paziewska, et al. "microRNA Profile of High-Grade B-Cell Lymphoma with 11q Aberration." International Journal of Molecular Sciences 26, no. 1 (2024): 285. https://doi.org/10.3390/ijms26010285.

Full text

Abstract:

High-grade B-cell lymphoma with 11q aberration (HGBCL-11q) is a rare germi-nal centre lymphoma characterised by a typical gain/loss pattern on chromo-some 11q but without MYC translocation. It shares some features with Burkitt lymphoma (BL), HGBCLs and germinal centre-derived diffuse large B-cell lym-phoma, not otherwise specified (GCB-DLBCL-NOS). Since microRNA expression in HGBCL-11q remains unknown, we aimed to identify and compare the mi-croRNA expression profiles in HGBCL-11q, BL and in GCB-DLBCL-NOS. Next-generation sequencing (NGS)-based microRNA profiling of HGBCL-11q (n = 6), BL (n =

APA, Harvard, Vancouver, ISO, and other styles

44

Zettl, Andreas, Silvia Bea, George Wright, et al. "Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work)." Blood 104, no. 11 (2004): 415. http://dx.doi.org/10.1182/blood.v104.11.415.415.

Full text

Abstract:

Abstract Introduction: Germinal center B-cell (GCB)-like and activated B-cell (ABC)-like diffuse large B-cell lymphomas (DLBCL) are characterized by different recurrent chromosomal imbalances. In a series of 177 untreated de novo DLBCL analyzed by comparative genomic hybridization (CGH), GCB-like DLBCL had shown more frequent gains of chromosome 12p/12cen-q14 (22% vs 5%, p=.0025), whereas ABC-like DLBCL had shown more frequent gains of 3/3q27-qter (34% vs 6%; p&lt;0.0001), 18q21 (36% vs 11%;p=0.0002) and losses of 6q21-q23 (36% vs 20%; p=0.0269). We investigated the impact of chromosomal i

APA, Harvard, Vancouver, ISO, and other styles

45

Cao, Y., T. Lin, S. Wang, et al. "A phase II study of R-CHOP in treatment of diffuse large B-cell lymphoma (DLBCL) subgroups." Journal of Clinical Oncology 24, no. 18_suppl (2006): 17540. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17540.

Full text

Abstract:

17540 Background: Recent studies with genes expression profiling and tissue microarray have divided the diffuse large B cell lymphoma (DLBCL) into prognostically important subgroups with germinal center B cell like (GCB) and non-GCB. However, these results are based on the samples of patients who were received standard CHOP regimen. Combination with CHOP and Rituximab (R-CHOP) has been proved to improve the survival of patients with DLBCL. To evaluate the efficacy of R-CHOP in different subgroups of DLBCL, this phase II study has been conducted. Methods: Previously untreated patients with DLBC

APA, Harvard, Vancouver, ISO, and other styles

46

Zhao, Peiqi, Huilai Zhang, Kai Fu, et al. "CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma." Blood 134, Supplement_1 (2019): 4117. http://dx.doi.org/10.1182/blood-2019-127666.

Full text

Abstract:

Purpose De novo CD5+ DLBCL is increasingly recognized as a distinct pathologic phenomenon with a specific clinical picture. However, De novo CD5+ DLBCL has not been studied on a large scale in China. In this study, we evaluated the frequency, clinicopathological characteristics of de novo CD5+ DLBCL and prognostic impact of CD5 expression, and patient survival in our center. Methods In this study, we retrospectively investigated 745 DLBCL cases treated at Tianjin medical university cancer institute and hospital between 2000 and 2017, sub-classifying them as germinal center B cell-like (GCB) an

APA, Harvard, Vancouver, ISO, and other styles

47

Feng, Ru, Xiaolei Wei, Meng Xu, et al. "STAT3 Predicts Poor Outcome In Patients With Advanced Diffuse Large B Cell Lymphoma." Blood 122, no. 21 (2013): 5069. http://dx.doi.org/10.1182/blood.v122.21.5069.5069.

Full text

Abstract:

Abstract Objective To explore the expression and prognosis of STAT3 in Chinese patients with diffuse large B-cell lymphoma (DLBCL). Methods The expression of STAT3 was examined by the immunohistochemistry (IHC) method.120 patients with de novo DLBCL were reviewed retrospectively. Results Among the 120 patients, the ratio of male to female was 1.26:1, 47.5% of them were Non-GCB and 52.5% were GCB-DLBCL. The expression of STAT3 was observed in 50 of 120 cases (41.7%) and more frequent in the non-germinal center B cell-like (Non-GCB) DLBCL than that in the GCB subtype. The prognosis analysis show

APA, Harvard, Vancouver, ISO, and other styles

48

Wang, Y. Lynn, Jiao Ma, Wei Xing, et al. "SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor." Blood 124, no. 21 (2014): 926. http://dx.doi.org/10.1182/blood.v124.21.926.926.

Full text

Abstract:

Abstract Non-Hodgkin Lymphoma (NHL) represents about 5 percent of all cancers diagnosed in the United States. While incidence of NHL has increased slightly over the past decade, death rates have been declining steadily. These declines in mortality can be attributed to improvements in treatment that are based on an increased understanding of the biology of the disease. Diffuse large B-cell lymphoma (DLBCL) accounts for ~30% of NHLs and greater than 80% of aggressive NHLs. Recent studies including large-scale genetic analyses have demonstrated the critical roles of the B-cell receptor’s (BCR) an

APA, Harvard, Vancouver, ISO, and other styles

49

Qu, Jie, Matthew J. Maurer, James R. Cerhan, et al. "Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL." Blood 128, no. 22 (2016): 5299. http://dx.doi.org/10.1182/blood.v128.22.5299.5299.

Full text

Abstract:

Abstract BACKGROUND: Diffuse large B-cell lymphoma, not otherwise specified (DLBCL), though defined as one disease entity, consists of two main cell-of-origin (COO) subtypes, germinal center B-cell like (GCB) and activated B-cell like (ABC), with the latter predicting a significantly worse prognosis using conventional chemotherapy. Up to 40% of all patients diagnosed with DLBCL will experience relapse, and outcomes are generally poor in this setting. In this study, we examine the proportion of GCB vs. non-GCB subtypes at initial diagnosis and at time of relapse, and assess the incidence of rec

APA, Harvard, Vancouver, ISO, and other styles

50

Ennishi, Daisuke, Ali Bashashati, Saeed Saberi, et al. "Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma." Blood 128, no. 22 (2016): 607. http://dx.doi.org/10.1182/blood.v128.22.607.607.

Full text

Abstract:

Abstract Diffuse large B cell lymphoma (DLBCL) comprises two distinct molecular subtypes: germinal center B cell (GCB) subtype and activated B cell (ABC) subtype. The pathogenesis of ABC-DLBCL is characterized by two processes - the activation of NF-KB and a block in terminal B-cell differentiation. However, in GCB-DLBCL only a few biologically relevant pathways have been identified, which has hampered the development of targeted therapies with specific efficacy in this subtype. Recurrent genetic alterations involved in PI3K-AKT signaling pathway have been identified in the patients with solid

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!